Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss - Probone I

Trial Profile

Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss - Probone I

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2012

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Acronyms Probone-I
  • Most Recent Events

    • 03 Jan 2012 New trial record
    • 10 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top